Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
IZEA Worldwide reported a net loss of $1.91 million for the nine months ended September 30, 2026, compared to a net income of $1.21 million in the prior year period, driven by a 26% decline in total revenue. The company maintained a strong cash position of $46.4 million despite the operational loss and continued investment in software development costs.
Viasat President, New Ventures Michael R. Kreller Sells $343K of Stock
Michael R. Kreller, President, New Ventures, sold 4,575 shares of Viasat Inc at $75.00 a share, worth $343K in total on Nov 10, 2026. Shares held after the trade: 5,147 (-47.1%).
NovoCure CFO Christoph Brackmann Sells $94.4K of Stock
Christoph Brackmann, CFO, sold 7,343 shares of NovoCure Ltd at $12.86 a share, worth $94.4K in total on Nov 9, 2026. Shares held after the trade: 175,499 (-4.0%).
MacroGenics reported a net loss of $20.1 million for the third quarter of 2026, compared to a net income of $16.8 million in the prior year period, primarily due to a significant decrease in collaborative revenue. The company completed the sale of its CDMO operations during the year, resulting in a $95.1 million net income from discontinued operations for the nine months ended September 30, 2026.
WidePoint Corp reported a significant revenue increase to $45.1 million for the quarter ended September 30, 2026, compared to $35.5 million in the prior year. Despite the revenue growth, the company recorded a net loss of $192,009 for the quarter, though this was an improvement from the $559,185 net loss reported in the same period of 2025.
Jaguar Uranium Corp. reported a net loss of $22.1 million for the nine months ended September 30, 2026, primarily driven by $17.7 million in non-cash charges related to liquidity and listing event shares following its IPO. The company significantly strengthened its balance sheet during the period, ending with $18.2 million in cash and short-term investments compared to $82,444 at the end of 2025.
American Integrity Insurance Group, Inc. reported a significant increase in total assets to $1.62 billion as of September 30, 2026, up from $1.23 billion at year-end 2025. The company, which completed its IPO in May 2025, saw its retained earnings grow to $291.6 million while maintaining a strong cash and investment position of over $777 million.
Mplx Exec VP & Chief Fin Ofc Carl Kristopher Hagedorn Sells $199K of Stock
Carl Kristopher Hagedorn, Exec VP & Chief Fin Ofc, sold 3,512 shares of Mplx LP at $56.74 a share, worth $199K in total on Nov 10, 2026. Shares held after the trade: 16,897 (-17.2%).
Liftoff Mobile reported Q3 2026 financial results with revenue of $238 million, up 32% year-over-year, and net income of $87 million. The company exceeded its previous guidance and issued an outlook for Q4 2026 revenue between $244 million and $249 million.
Term
Q3 2026
“Our third quarter results came in well above the high end of our previously published guidance and showed the breadth of the app economy at work. We saw strength across key app categories, as better performance for our customers drove more investment in our platform and strengthened our flywheel. We’re confident that our platform is purpose built to capture user attention and monetization for our customers.”
Jeremy Bondy, Liftoff’s Chief Executive Officer
“Our strong Q3 financial results demonstrated the earnings power of our business as we build our track record as a public company. We remain focused on delivering durable and profitable growth and strong cash generation.”
Tarek Kutrieh, Liftoff’s President and Chief Financial Officer
SELLAS Life Sciences reported its third quarter 2026 financial results, highlighting a cash position of $134.7 million. The company expects to report topline primary endpoint results from its Phase 3 REGAL trial of GPS in AML later this month and preliminary topline data for SLS009 in first-line AML in Q4 2026.
Term
Q3 2026
“We continue to execute across both of our clinical programs as we approach several important milestones. In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month. If successful, we believe GPS could be a transformative new immunotherapy for AML patients in second complete remission.”
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer
“In parallel, enrollment and dosing continue in our Phase 2 trial of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter. As announced earlier this month, we look forward to presenting our Phase 2 data in relapsed/refractory AML at the upcoming ASH in December. We were also encouraged by the preclinical data presented at AACR in pancreatic cancer models, including in resistance to a RAS inhibitor, and we are continuing our preparations for clinical development in that indication. With $134.7 million in cash and cash equivalents as of September 30, we are well positioned to further advance these programs.”
Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer
DTE Electric $600M Debt Financing with U.S. Bank Trust Company, National Association
DTE Electric Securitization Funding III LLC, a subsidiary of DTE Electric Company, issued $600.46 million of Series 2026A Senior Secured Securitization Bonds. The bonds were issued under an indenture and series supplement dated November 12, 2026, to securitize certain utility properties and related rights.
Knightscope reported Q3 2026 revenue of $8.7 million, a 177% increase year-over-year, driven by its new Autonomous Security Force managed service strategy. The company achieved a positive gross margin of $0.4 million compared to a gross loss in the prior year, though it recorded a net loss of $11.8 million for the quarter.
Term
Q3 2026
“We delivered our third consecutive quarter of triple-digit revenue growth, and positive gross margin in our services business. This year we redefined our go-to-market strategy around delivering security outcomes - autonomous machines, AI-driven software, and licensed security agents operating as one accountable operation under one contract.”
William Santana Li, Founder, Chairman and CEO of Knightscope
“Our priorities are clear: convert the approximately $27 million in renewals, bookings, and client awards secured since May 2026 into revenue, expand with the clients we already serve, and drive margins higher.”
William Santana Li, Founder, Chairman and CEO of Knightscope
Streamex Corp. reported Q3 2026 financial results, highlighting a net loss of $17.5 million and a total liquidity position of $36.5 million. The company saw significant growth in its tokenized gold product (GLDY), with assets under management reaching $14.0 million and external ownership doubling to 17.7%.
Term
Q3 2026
“Q1 launched GLDY, Q2 built the distribution around it, and Q3 was about scaling that distribution and adoption. Over the last ninety days, an institutional investment manager began running a gold carry strategy with GLDY as its long leg, outside ownership doubled, and the Cask Foundation began bootstrapping liquidity for its first product, USGY.”
Henry McPhie, Co-Founder and Chief Executive Officer
Azora Therapeutics reported its third quarter 2026 financial results, highlighting its recent transition to the Nasdaq under the ticker 'AZR' and the appointment of a new executive leadership team. The company remains on track to submit an IND and initiate a Phase 1a trial for its lead candidate AT177 in the first half of 2027.
“With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis. We are pleased to have recently strengthened our leadership team, appointing Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist. Dr. Rubenstein led the development and FDA approval of the first AhR agonist. We have further added to our depth of experience through the appointment of new Board members who bring inflammatory disease, clinical development and company building expertise to Azora. Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.”
Matt Davidson, Ph.D., President, Co-Founder and Chief Executive Officer
Evommune, Inc. reported financial results for the third quarter ended September 30, 2026, and provided a business update on its immunology pipeline. The company highlighted the in-licensing of EVO570, positive Phase 2a data for EVO301 in atopic dermatitis, and confirmed a cash runway extending into the second half of 2029.
“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved.”
Luis Peña, President and Chief Executive Officer
“As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756. With a strong balance sheet and an experienced team, we believe we are well positioned to deliver on these milestones and create meaningful value for patients and stockholders.”
Intapp Insider Nancy L. Harris Sells $290K of Stock
Nancy L. Harris sold 6,512 shares of Intapp, Inc. at $43.77 to $45.00 a share (average $44.56) in 3 transactions, worth $290K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 34,907 (-8.5%).
AIRO Group Holdings reported revenue of $69.6 million for the nine months ended September 30, 2026, a significant increase from $42.6 million in the prior year period. Despite higher gross profits, the company incurred a net loss of $29.4 million due to increased research and development and general administrative expenses.
BioCardia, Inc. reported a net loss of $5.7 million for the nine months ended September 30, 2026, compared to a $6.2 million loss in the prior year period. The company ended the quarter with $2.2 million in cash and cash equivalents, supported by $5.3 million in proceeds from common stock sales during the year.
Cyngn Inc. reported a net loss of $18.8 million for the nine months ended September 30, 2026, compared to $17.8 million in the prior year period, despite a significant increase in revenue to $405,527. The company strengthened its cash position through $17.9 million in financing activities, including at-the-market and public stock offerings, ending the period with $3.1 million in cash and $31.8 million in short-term investments.
Knightscope, Inc. reported a significant decrease in cash and cash equivalents from $20.6 million at the end of 2025 to $6.8 million as of September 30, 2026. The company's total assets increased to $52.2 million, primarily driven by a substantial rise in goodwill and intangible assets following acquisitions, while management expressed substantial doubt about the company's ability to continue as a going concern.
United States Antimony Corp reported a significant increase in net loss to $20.7 million for the nine months ended September 30, 2026, compared to $4.1 million in the prior year, driven by a sharp rise in operating expenses and mineral exploration costs. Despite the loss, the company strengthened its balance sheet through common stock issuances, ending the period with $171.9 million in total stockholders' equity.
Relmada Therapeutics reported a net loss of $45.8 million for the nine months ended September 30, 2026, compared to $37.5 million in the prior year, driven by increased research and development costs. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $202.1 million in cash and short-term investments.
Cisco reported record first quarter fiscal 2027 revenue of $18.5 billion, a 24% increase year-over-year, driven by high demand for AI infrastructure and networking technology. The company raised its full-year fiscal 2027 revenue guidance to a range of $74.8 billion to $75.8 billion and increased its AI infrastructure revenue expectations from hyperscalers to $9 billion.
Term
Q1 2027
“In Q1, we delivered the strongest revenue and non-GAAP earnings per share growth rates for Cisco in over 15 years. Organizations are turning to Cisco for our trusted, market-defining technology and our expertise to help them scale, secure and optimize their environments for the agentic AI era. We are in the very early stages of a multi-year networking supercycle, and we're confident in our ability to continue capturing the multi-billion-dollar opportunity it represents for Cisco.”
Chuck Robbins, chair and CEO of Cisco
“Q1 FY27 was another record quarter for Cisco, with revenue, non-GAAP operating margin, and non-GAAP EPS all exceeding the high end of our guidance ranges. The strength of our Q1 performance gives us confidence to raise our revenue and non-GAAP EPS guidance for FY27. As our business continues to scale, we are unlocking significant operating leverage which is enabling us to grow earnings much faster than revenue. Looking ahead, we remain focused on delivering durable growth and driving continued capital returns.”
Yvonne Genovese, EVP, Bus. & Tech. Insights, sold 524 shares of Gartner Inc at $190.30 a share, worth $99.7K in total on Nov 9, 2026. Shares held after the trade: 5,684 (-8.4%).
Genpact Limited held a special general meeting of shareholders on November 10, 2026, where shareholders approved a proposal to change the company's jurisdiction of incorporation from Bermuda to the State of Delaware. The domestication involves discontinuing as a Bermuda exempted company and continuing as a Delaware corporation.
Hyatt Hotels $400M Debt Financing with Computershare Trust Company, N.A.
Hyatt Hotels Corporation completed a public offering of $400 million in 5.950% Senior Notes due 2033. The company received net proceeds of approximately $395.3 million, which it intends to use alongside excess cash to repay its outstanding 5.750% notes due 2027 and for general corporate purposes.
Vuzix Corp reported total sales of $0.7 million for the quarter ended September 30, 2026, down from $1.2 million in the prior year period. The company experienced a net loss of $8.4 million for the quarter and $23.1 million for the first nine months of 2026, while maintaining a cash balance of $9.2 million.
AmpliTech Group reported a net loss of $6.5 million for the nine months ended September 30, 2026, compared to a $3.8 million loss in the prior year period. Despite a slight decrease in nine-month revenue, the company significantly strengthened its balance sheet, increasing cash and marketable securities to over $30 million following successful rights and direct offerings.
EyePoint, Inc. reported a significant increase in net loss to $274.9 million for the nine months ended September 30, 2026, driven primarily by a surge in research and development expenses to $237.4 million. Total revenues declined sharply from $30.8 million to $2.0 million year-over-year, largely due to the absence of significant license and collaboration revenue seen in 2025.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on genetic medicines for rare diseases. As of September 30, 2026, the company is classified as a non-accelerated filer and smaller reporting company with 111,660,283 shares of common stock outstanding.